=> d his

(FILE 'HOME' ENTERED AT 16:38:29 ON 22 JAN 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 16:38:44 ON 22 JAN 2003

L1 8417 S AAV OR ADENO-ASSOCIATED(W)VIRUS
L2 39510 S (CNS OR CENTRAL(W)NERVOUS(W)SYSTEM)(6A)(DISEASE OR DISORDER)
L3 364965 S (PARKINSON OR ALZHEIMER)(3A)DISEASE OR GLIOMA OR GLIOBLASTOMA
L4 53458 S BRAIN(3A)(TUMOR OR CANCER)
L5 436225 S L2 OR L3 OR L4
L6 89 S L1(8A)L5
L7 117 S CONVECTION(3A)ENHANCED(3A)DELIVERY
L8 3 S L6 AND L7
L9 3 DUP REM L8 (0 DUPLICATES REMOVED)

=> d bib ab 1-3 l9

L9 ANSWER 1 OF 3 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 2002:236247 SCISEARCH
GA The Genuine Article (R) Number: 529FG
TI Gene therapeutic approaches to the treatment of Parkinson's disease
AU Bowers W J; Maguire-Zeiss K A; Harvey B K; Federoff H J (Reprint)
CS Univ Rochester, Sch Med & Dent, Ctr Aging & Dev Biol, Div Mol Med & Gene Therapy, 601 Elmwood Ave, Rochester, NY 14642 USA (Reprint); Univ Rochester, Sch Med & Dent, Ctr Aging & Dev Biol, Div Mol Med & Gene Therapy, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Neurobiol & Anat, Rochester, NY 14642 USA
CYA USA
SO CLINICAL NEUROSCIENCE RESEARCH, (DEC 2001) Vol. 1, No. 6, pp. 483-495. Publisher: ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND.
ISSN: 1566-2772.
DT General Review; Journal
LA English
REC Reference Count: 177
*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
AB Parkinson's disease (PD) is a neurodegenerative illness of unknown etiology that presently has no cure. Symptoms of this progressively debilitating disease include bradykinesia, resting tremor, rigidity, gait abnormalities, and postural instability that can be transiently alleviated via continued administration of the drug, L-DOPA. However, following prolonged usage, the effectiveness of this clinical treatment substantially diminishes. To that end, novel therapies for amelioration of symptoms and/or permanent cure of PD need to be developed. The utility of gene transfer modalities for PD treatment holds tremendous promise, but gene therapy is yet unproven within the realm of the **central nervous system**. This discourse proposes possible **disease** targets and reviews the present standing of adenovirus-, **adeno-associated virus**-, herpes virus-, and non-virus-based gene transfer technologies in regard to how they have been applied in in vitro and in vivo models of PD. Identification of disease mechanisms, potential points of therapeutic intervention, and an understanding of presently utilized gene delivery vehicles will facilitate the development of potentially safe and efficacious modalities for therapy of PD. (C) 2001 Elsevier Science B.V. All rights reserved.

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 2000:442913 CAPLUS
DN 134:36883
TI **Convection-enhanced delivery** of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach

AU Bankiewicz, Krys S.; Eberling, Jamie L.; Kohutnicka, Malgorzata; Jagust, William; Pivirotto, Phillip; Bringas, John; Cunningham, Janet; Budinger, Thomas F.; Harvey-White, Judith
CS Molecular Therapeutics Section, LMMN, NINDS, Bethesda, MD, 20892, USA
SO Experimental Neurology (2000), 164(1), 2-14
CODEN: EXNEAC; ISSN: 0014-4886
PB Academic Press
DT Journal
LA English
AB Using an approach that combines gene therapy with arom. l-amino acid decarboxylase (AADC) gene and a pro-drug (l-dopa), dopamine, the neurotransmitter involved in Parkinson's disease, can be synthesized and regulated. Striatal neurons infected with the AADC gene by an adeno-assocd. viral vector can convert peripheral l-dopa to dopamine and may therefore provide a buffer for unmetabolized l-dopa. This approach to treating Parkinson's disease may reduce the need for l-dopa/carbidopa, thus providing a better clin. response with fewer side effects. In addn., the imbalance in dopamine prodn. between the nigrostriatal and mesolimbic dopaminergic systems can be cor. by using AADC gene delivery to the striatum. We have also demonstrated that a fundamental obstacle in the gene therapy approach to the central nervous system, i.e., the ability to deliver viral vectors in sufficient quantities to the whole brain, can be overcome by using **convection-enhanced delivery** . Finally, this study demonstrates that positron emission tomog. and the AADC tracer, 6-[18F]fluoro-l-m-tyrosine, can be used to monitor gene therapy in vivo. Our therapeutic approach has the potential to restore dopamine prodn., even late in the disease process, at levels that can be maintained during continued nigrostriatal degeneration. (c) 2000 Academic Press.
RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 1999:763910 CAPLUS
DN 132:19624
TI **Convection-enhanced delivery** of AAV vectors to the CNS and therapeutic use thereof
IN Bankiewicz, Krys; Cunningham, Janet; Eberling, Jamie L.
PA Avigen, Inc., USA; Lawrence Berkeley National Laboratory
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 9961066 | A2 | 19991202 | WO 1999-US11687 | 19990526 |
| | WO 9961066 | A3 | 20000504 | | |
| | W: CA, JP | | | | |
| | RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | CA 2329259 | AA | 19991202 | CA 1999-2329259 | 19990526 |
| | EP 1080202 | A2 | 20010307 | EP 1999-925906 | 19990526 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | US 6309634 | B1 | 20011030 | US 1999-320171 | 19990526 |
| | JP 2002516295 | T2 | 20020604 | JP 2000-550525 | 19990526 |
| | US 2002141980 | A1 | 20021003 | US 2001-887854 | 20010621 |
| PRAI | US 1998-86949P | P | 19980527 | | |
| | US 1999-134748P | P | 19990518 | | |
| | US 1999-320171 | A1 | 19990526 | | |
| | WO 1999-US11687 | W | 19990526 | | |

AB Methods of delivering viral vectors, particularly recombinant adeno-assocd. virions, to the CNS are provided. Also provided are methods

of treating Parkinson's Disease.

=>

=> d his

(FILE 'HOME' ENTERED AT 15:59:28 ON 22 JAN 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 15:59:40 ON 22 JAN 2003

L1 8417 S AAV OR ADENO-ASSOCIATED(W)VIRUS
L2 39510 S (CNS OR CENTRAL(W)NERVOUS(W)SYSTEM)(6A)(DISEASE OR DISORDER)
L3 380042 S (PARKINSON OR ALZHEIMER)(3A)DISEASE OR GLIOMA OR NEUROBLASTOM
L4 416034 S L2 OR L3
L5 250 S L1(S)L4
L6 83 S L1(8A)L4
L7 54 DUP REM L6 (29 DUPLICATES REMOVED)

=> d 20-54 au ti so l7

L7 ANSWER 20 OF 54 SCISEARCH COPYRIGHT 2003 ISI (R)
AU Bowers W J; Maguire-Zeiss K A; Harvey B K; Federoff H J (Reprint)
TI Gene therapeutic approaches to the treatment of Parkinson's disease
SO CLINICAL NEUROSCIENCE RESEARCH, (DEC 2001) Vol. 1, No. 6, pp. 483-495. Publisher: ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND.
ISSN: 1566-2772.

L7 ANSWER 21 OF 54 CAPLUS COPYRIGHT 2003 ACS
AU Sanchez-Pernaute, Rosario; Harvey-White, Judith; Cunningham, Janet; Bankiewicz, Krys S.
TI Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats
SO Molecular Therapy (2001), 4(4), 324-330
CODEN: MTOHCK; ISSN: 1525-0016

L7 ANSWER 22 OF 54 CAPLUS COPYRIGHT 2003 ACS
AU Mochizuki, Hideki; Mizuno, Yoshikuni
TI Mitochondria and degenerative disorder
SO Igaku no Ayumi (2001), 199(4), 263-267
CODEN: IGAYAY; ISSN: 0039-2359

L7 ANSWER 23 OF 54 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AU Du Xucang (1); Ren Huimin (1); Hu Haitao (1)
TI Gene therapy vector based on adeno-associated virus type-2.
SO Xi'an Yike Daxue Xuebao, (Apr., 2001) Vol. 22, No. 2, pp. 100-102. print.
ISSN: 0258-0659.

L7 ANSWER 24 OF 54 CAPLUS COPYRIGHT 2003 ACS
AU Klein, Ronald L.; Mandel, Ronald J.; Muzyczka, Nicholas
TI Adeno-associated virus vector-mediated gene transfer to somatic cells in the central nervous system
SO Advances in Virus Research (2000), 55, 507-528
CODEN: AVREA8; ISSN: 0065-3527

L7 ANSWER 25 OF 54 MEDLINE DUPLICATE 6
AU Ozawa K; Fan D S; Shen Y; Muramatsu S; Fujimoto K; Ikeguchi K; Ogawa M; Urabe M; Kume A; Nakano I
TI Gene therapy of **Parkinson**'s **disease** using **adeno-associated virus** (**AAV**) vectors.
SO JOURNAL OF NEURAL TRANSMISSION. SUPPLEMENTUM, (2000) (58) 181-91. Ref: 56
Journal code: 0425126. ISSN: 0303-6995.

L7 ANSWER 26 OF 54 CAPLUS COPYRIGHT 2003 ACS
AU Ozawa, K.; Fan, D. -S.; Shen, Y.; Muramatsu, S.; Fujimoto, K.; Ikeguchi,

K.; Ogawa, M.; Urabe, M.; Kume, A.; Nakano, I.
TI Gene therapy of **Parkinson**'s **disease** using **adeno-associated virus** (**AAV**) vectors
SO Advances in Research on Neurodegeneration (2000), 7(7th International Winter Conference on Neurodegeneration, 1999), 181-191
CODEN: ARNEFX; ISSN: 1068-719X

L7 ANSWER 27 OF 54 MEDLINE DUPLICATE 7
AU Bjorklund A; Kirik D; Rosenblad C; Georgievska B; Lundberg C; Mandel R J
TI Towards a neuroprotective gene therapy for **Parkinson**'s **disease**: use of adenovirus, **AAV** and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
SO BRAIN RESEARCH, (2000 Dec 15) 886 (1-2) 82-98. Ref: 71
Journal code: 0045503. ISSN: 0006-8993.

L7 ANSWER 28 OF 54 CAPLUS COPYRIGHT 2003 ACS
AU Bankiewicz, Krys S.; Eberling, Jamie L.; Kohutnicka, Malgorzata; Jagust, William; Pivirotto, Phillip; Bringas, John; Cunningham, Janet; Budinger, Thomas F.; Harvey-White, Judith
TI Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach
SO Experimental Neurology (2000), 164(1), 2-14
CODEN: EXNEAC; ISSN: 0014-4886

L7 ANSWER 29 OF 54 CAPLUS COPYRIGHT 2003 ACS
IN Bankiewicz, Krys; Cunningham, Janet; Eberling, Jamie L.
TI Convection-enhanced delivery of AAV vectors to the CNS and therapeutic use thereof
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2

L7 ANSWER 30 OF 54 CAPLUS COPYRIGHT 2003 ACS
IN Schenk, Dale B.
TI Prevention and treatment of amyloidogenic disease, especially Alzheimer's disease, based on induction of anti-amyloid immune response
SO PCT Int. Appl., 113 pp.
CODEN: PIXXD2

L7 ANSWER 31 OF 54 CAPLUS COPYRIGHT 2003 ACS
IN Breakefield, Xandra O.; Jacoby, David R.; Smith, Frances I.
TI HSV/AAV hybrid amplicon vector system for gene therapy of cancer, deficiency state diseases and genetic disorders
SO U.S., 22 pp.
CODEN: USXXAM

L7 ANSWER 32 OF 54 MEDLINE DUPLICATE 8
AU Jacobs A; Breakefield X O; Fraefel C
TI HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.
SO NEOPLASIA, (1999 Nov) 1 (5) 402-16. Ref: 202
Journal code: 100886622. ISSN: 1522-8002.

L7 ANSWER 33 OF 54 MEDLINE DUPLICATE 9
AU Lo W D; Qu G; Sferra T J; Clark R; Chen R; Johnson P R
TI Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression.
SO HUMAN GENE THERAPY, (1999 Jan 20) 10 (2) 201-13.
Journal code: 9008950. ISSN: 1043-0342.

L7 ANSWER 34 OF 54 CAPLUS COPYRIGHT 2003 ACS
AU Mi, Jie; Chatterjee, Saswati; Wong, Kamehameha K.; Forbes, Chelsea; Lawless, George; Tobin, Allan J.

TI Recombinant adeno-associated virus (AAV) drives constitutive production of glutamate decarboxylase in neural cell lines
SO Journal of Neuroscience Research (1999), 57(1), 137-148
CODEN: JNREDK; ISSN: 0360-4012

L7 ANSWER 35 OF 54 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 10
AU Ozawa, K.; Fan, D.; Ogawa, M.; Urabe, M.; Kume, A.; Monahan, J.; Nakano, I.
TI Strategies for gene therapy of **Parkinson's disease** using **adeno-associated virus** (**AAV**) vectors
SO Biogenic Amines (1999), 15(1), 21-27
CODEN: BIAME7; ISSN: 0168-8561

L7 ANSWER 36 OF 54 SCISEARCH COPYRIGHT 2003 ISI (R)
AU Zhu J H (Reprint); Black P; Zhang L; Carter B; Kuo C J; Folkman J; Mulligan R C
TI Sustained inhibition of **brain tumor** growth by recombinant **adeno-associated virus** encoding endostatin
SO GENE THERAPY, (OCT 1999) Vol. 6, Supp. [1], pp. 1-1.
Publisher: STOCKTON PRESS, HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND.
ISSN: 0969-7128.

L7 ANSWER 37 OF 54 CAPLUS COPYRIGHT 2003 ACS
IN Breakefield, Xandra O.; Jacoby, David R.; Smith, Frances I.
TI Construction and therapeutic use of herpes simplex/adeno-associated virus hybrid amplicon vectors
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2

L7 ANSWER 38 OF 54 MEDLINE DUPLICATE 11
AU Mandel R J; Rendahl K G; Spratt S K; Snyder R O; Cohen L K; Leff S E
TI Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease.
SO JOURNAL OF NEUROSCIENCE, (1998 Jun 1) 18 (11) 4271-84.
Journal code: 8102140. ISSN: 0270-6474.

L7 ANSWER 39 OF 54 CAPLUS COPYRIGHT 2003 ACS
AU Fan, Dong-Sheng; Ogawa, Matsuo; Fujimoto, Ken-Ichi; Ikeguchi, Kunihiko; Ogasawara, Yoji; Urabe, Masashi; Kume, Akihiro; Nishizawa, Masatoyo; Nakano, Imaharu; Yoshida, Mitsuo; Ichinose, Hiroshi; Nagatsu, Toshiharu; Kurtzman, Gary J.; Ozawa, Keiya
TI Gene therapy of a rodent model of **Parkinson's disease** using **adeno-associated virus** (**AAV**) vectors
SO Advances in Behavioral Biology (1998), 49(Progress in Alzheimer's and Parkinson's Diseases), 647-652
CODEN: ADBBBW; ISSN: 0099-6246

L7 ANSWER 40 OF 54 SCISEARCH COPYRIGHT 2003 ISI (R)
AU Leff S E (Reprint); Spratt S K; Snyder R O; Mandel R J
TI Long term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant **AAV** vector gene transfer in a rodent model of **Parkinson's disease**
SO EXPERIMENTAL NEUROLOGY, (OCT 1998) Vol. 153, No. 2, pp. 383-383.
Publisher: ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495.
ISSN: 0014-4886.

L7 ANSWER 41 OF 54 CAPLUS COPYRIGHT 2003 ACS
AU Mizuno, Masaaki; Yoshida, Jun

TI Improvement of transduction efficiency of recombinant adeno-associated virus vector by entrapment in multilamellar liposomes
SO Japanese Journal of Cancer Research (1998), 89(4), 352-354
CODEN: JJCREP; ISSN: 0910-5050

L7 ANSWER 42 OF 54 CAPLUS COPYRIGHT 2003 ACS
AU Mizuno, Masaaki; Yoshida, Jun; Colosi, Peter; Kurtzman, Gary
TI Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration
SO Japanese Journal of Cancer Research (1998), 89(1), 76-80
CODEN: JJCREP; ISSN: 0910-5050

L7 ANSWER 43 OF 54 CAPLUS COPYRIGHT 2003 ACS
AU Mandel, R. J.; Spratt, S. K.; Snyder, R. O.; Leff, S. E.
TI Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats
SO Proceedings of the National Academy of Sciences of the United States of America (1997), 94(25), 14083-14088
CODEN: PNASA6; ISSN: 0027-8424

L7 ANSWER 44 OF 54 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AU Leff, S. E.; Clevenger, D.; Wu, F.; Li, J.; John, J.; Snyder, R.; Kaspar, B.; Jaret, T.; Spratt, S. K.; Mandel, R. J.
TI Towards a gene therapy for **Parkinson**'s **disease** (PD): Intrastriatal injection of recombinant **adeno-associated virus** (rAAV) encoding human L-aromatic amino-acid decarboxylase (hAADC) in 6-OHDA lesioned rats restores AADC activity to control levels.
SO Society for Neuroscience Abstracts, (1997) Vol. 23, No. 1-2, pp. 541.
Meeting Info.: 27th Annual Meeting of the Society for Neuroscience, Part 1 New Orleans, Louisiana, USA October 25-30, 1997
ISSN: 0190-5295.

L7 ANSWER 45 OF 54 MEDLINE DUPLICATE 12
AU Johnston K M; Jacoby D; Pechan P A; Fraefel C; Borghesani P; Schuback D; Dunn R J; Smith F I; Breakefield X O
TI HSV/**AAV** hybrid amplicon vectors extend transgene expression in human **glioma** cells.
SO HUMAN GENE THERAPY, (1997 Feb 10) 8 (3) 359-70.
Journal code: 9008950. ISSN: 1043-0342.

L7 ANSWER 46 OF 54 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AU McQuiston, S. (1); Couto, L.; Fick, J.; Israel, M.; Kurtzman, G.; Podsakoff, G.
TI **Adeno-associated virus** (**AAV**) vector delivery of HSV-tk causes **glioma** regression after ganciclovir administration.
SO Proceedings of the American Association for Cancer Research Annual Meeting, (1997) Vol. 38, No. 0, pp. 176.
Meeting Info.: Eighty-eighth Annual Meeting of the American Association for Cancer Research San Diego, California, USA April 12-16, 1997
ISSN: 0197-016X.

L7 ANSWER 47 OF 54 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AU Herrlinger, U. (1); Breakefiled, X. O.; Jacoby, D.; Fraefel, C.; Spear, M. A.; Schuback, D.; Pechan, P. A.; Smith, F.; Johnston, K. M.
TI Transduction of human **glioma** cells by HSV/**AAV** hybrid vectors is increased by ionizing radiation.
SO Proceedings of the American Association for Cancer Research Annual Meeting, (1997) Vol. 38, No. 0, pp. 13.
Meeting Info.: Eighty-eighth Annual Meeting of the American Association

for Cancer Research San Diego, California, USA April 12-16, 1997
ISSN: 0197-016X.

L7 ANSWER 48 OF 54 MEDLINE DUPLICATE 13
AU Okada H; Miyamura K; Itoh T; Hagiwara M; Wakabayashi T; Mizuno M; Colosi P; Kurtzman G; Yoshida J
TI Gene therapy against an experimental **glioma** using **adeno -associated virus** vectors.
SO GENE THERAPY, (1996 Nov) 3 (11) 957-64.
Journal code: 9421525. ISSN: 0969-7128.

L7 ANSWER 49 OF 54 CAPLUS COPYRIGHT 2003 ACS
IN Johnson, Philip R.
TI Recombinant adeno-associated virus vectors encoding immunodeficiency virus protein and their clinical use
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2

L7 ANSWER 50 OF 54 MEDLINE
AU Tenenbaum L; Darling J L; Hooghe-Peters E
TI Adeno-associated virus (AAV) as a vector for gene transfer into glial cells of the human central nervous system.
SO GENE THERAPY, (1994) 1 Suppl 1 S80.
Journal code: 9421525. ISSN: 0969-7128.

L7 ANSWER 51 OF 54 MEDLINE DUPLICATE 14
AU Wu P; Ziska D; Bonell M A; Grouzmann E; Millard W J; Meyer E M
TI Differential neuropeptide Y gene expression in post-mitotic versus dividing **neuroblastoma** cells driven by an **adeno-associated virus** vector.
SO BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH, (1994 Jul) 24 (1-4) 27-33.
Journal code: 8908640. ISSN: 0169-328X.

L7 ANSWER 52 OF 54 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AU Bryant, S. O.; De Fiebre, C. M.; Notabartolo, D.; Wu, P.; King, M.; Meyer, E. M.
TI Use of reconstituted Sendai viral envelopes to deliver an NPY containing **adeno-associated virus** vector to **neuroblastoma** and brain cells.
SO Journal of the American Geriatrics Society, (1993) Vol. 41, No. 10 SUPPL., pp. SA2.
Meeting Info.: 50th Annual Scientific Meeting of the American Geriatrics Society and the 14th Annual Scientific Meeting of the American Federation for Aging Research New Orleans, Louisiana, USA November 15-19, 1993
ISSN: 0002-8614.

L7 ANSWER 53 OF 54 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AU De Fiebre, C. M.; Notabartolo, D.; Wu, P.; Meyer, F. M.
TI Use of reconstituted Sendai viral envelopes to deliver a NPY-containing **adeno-associated virus** vector to **neuroblastoma** and glial cells in culture.
SO Society for Neuroscience Abstracts, (1992) Vol. 18, No. 1-2, pp. 781.
Meeting Info.: 22nd Annual Meeting of the Society for Neuroscience Anaheim, California, USA October 25-30, 1992
ISSN: 0190-5295.

L7 ANSWER 54 OF 54 MEDLINE
AU Lipps B V; Mayor H D
TI Properties of adeno-associated virus (type 1) replicated in rodent cells by murine adenovirus.
SO JOURNAL OF GENERAL VIROLOGY, (1980 Nov) 51 (Pt 1) 223-7.
Journal code: 0077340. ISSN: 0022-1317.

=> d bib ab 31 37 49 l7

L7 ANSWER 31 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1999:655915 CAPLUS
DN 131:282393
TI HSV/AAV hybrid amplicon vector system for gene therapy of cancer, deficiency state diseases and genetic disorders
IN Breakefield, Xandra O.; Jacoby, David R.; Smith, Frances I.
PA The General Hospital Corporation, USA
SO U.S., 22 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI US 5965441 | A | 19991012 | US 1997-968434 | 19971112 |
| PRAI US 1996-30694P | P | 19961113 | | |

AB The present invention relates to a hybrid vector system which incorporates elements of herpesvirus and adeno-assocd. virus and which is capable of expressing a gene product in eukaryotic cells. The vector system of the present invention provides a means of packaging plasmid DNA into highly infectious virions which can efficiently and safely deliver large transgenes to both mitotic and postmitotic cells in a state which can be maintained for extended periods. The invention pertains to the use of this vector system in introducing and expressing gene sequences in mitotic and postmitotic cells. This HSV/AAV hybrid amplicon vector system can be used in gene therapy for treating various cancers and deficiency state disorders.
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 37 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1998:344520 CAPLUS
DN 129:13209
TI Construction and therapeutic use of herpes simplex/adeno-associated virus hybrid amplicon vectors
IN Breakefield, Xandra O.; Jacoby, David R.; Smith, Frances I.
PA General Hospital Corp., USA; Eunice Kennedy Shriver Center for Mental Retardation, Inc.
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 9821345 | A1 | 19980522 | WO 1997-US20422 | 19971112 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| AU 9851999 | A1 | 19980603 | AU 1998-51999 | 19971112 |
| EP 946733 | A1 | 19991006 | EP 1997-946914 | 19971112 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2002503086 | T2 | 20020129 | JP 1998-522710 | 19971112 |
| PRAI US 1996-747919 | A | 19961112 | | |
| WO 1997-US20422 | W | 19971112 | | |

AB The present invention relates to a hybrid vector system which incorporates

elements of herpes simplex virus (HSV) and adeno-assocd. virus (AAV) which are capable of expressing a gene product in eukaryotic cells. The vector system of the present invention provides a means of packaging plasmid DNA into highly infectious virions which can efficiently and safely deliver large transgenes to both mitotic and postmitotic cells in a state which can be maintained for extended periods. The HSV amplicon elements comprise the DNA replication origin (oriS) and the virion packaging signal pac. The AAV elements are the DNA terminal repeats (ITRs) which are sufficient for replication and packaging of AAV virions, and the rep gene which encodes proteins for replication and chromosomal integration pf ITR-flanked sequences. The invention pertains to the use of this vector system in introducing and expressing gene sequences in mitotic and postmitotic cells for therapeutic purposes. Diseases and disorders potentially treatable include lysosomal storage disease, Lesch-Nyhan syndrome, amyloid polyneuropathy, Alzheimer's, Duchenne's muscular dystrophy, ALS, Parkinson's disease and brain tumors. Other treatable diseases are sickle-cell anemia, clotting disorders, thalassemias, cystic fibrosis, diabetes, liver and lung disorders, heart and vascular disease, hormone deficiency diseases, movement disorders, pain, and stoke. Treatable neoplastic-type diseases treatable include HIV tumors, neoplasms, carcinomas, sarcomas, leukemias, lymphoma, astrocytomas, oligodendrogliomas, meningiomas, neurofibromas, ependymomas, Schwannomas, neurofibrosarcomas, and glioblastomas. The amplicon vector method is exemplified by administration of a cytochrome P 450 enzyme, cyclophosphamide, or ifosphamide as chemotherapeutic agent to CNS tumor cells.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 49 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1996:106583 CAPLUS
DN 124:137857
TI Recombinant adeno-associated virus vectors encoding immunodeficiency virus protein and their clinical use
IN Johnson, Philip R.
PA Children's Hospital, Inc., USA
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 9534670 | A2 | 19951221 | WO 1995-US7178 | 19950606 |
| | WO 9534670 | A3 | 19960613 | | |
| | W: AU, CA, JP | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | US 5658785 | A | 19970819 | US 1994-254358 | 19940606 |
| | CA 2192215 | AA | 19951221 | CA 1995-2192215 | 19950606 |
| | AU 9531243 | A1 | 19960105 | AU 1995-31243 | 19950606 |
| | AU 710804 | B2 | 19990930 | | |
| | EP 764213 | A1 | 19970326 | EP 1995-927113 | 19950606 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| | JP 10504185 | T2 | 19980428 | JP 1995-502305 | 19950606 |
| | US 5786211 | A | 19980728 | US 1995-475391 | 19950607 |
| | US 5858775 | A | 19990112 | US 1996-709609 | 19960910 |
| | US 2002159979 | A1 | 20021031 | US 2002-77294 | 20020215 |
| | US 2002187129 | A1 | 20021212 | US 2002-163886 | 20020604 |
| PRAI | US 1994-254358 | A | 19940606 | | |
| | US 1995-466606 | B1 | 19950606 | | |
| | WO 1995-US7178 | W | 19950606 | | |
| | US 1998-12132 | B1 | 19980122 | | |
| | US 1999-292703 | B1 | 19990415 | | |
| | US 2000-691604 | A1 | 20001018 | | |

US 2002-77294 A1 20020215

AB The present invention provides adeno-assocd. virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV) genomes, comprising adeno-assocd. virus inverted terminal repeats flanking DNA sequences encoding an immunodeficiency virus protein operably linked to promoter and polyadenylation sequences, methods for packaging rAAV genomes, stable host cell lines producing rAAV and methods for delivering genes of interest to cells utilizing the rAAV. Particularly disclosed are rAAV useful in generating immunity to human immunodeficiency virus-1 and in therapeutic gene delivery for treatment of neurol. disorders.

=>